Acne gel
This combination of clindamycin (1%) and tretinoin (0.025%), solubilized in a hydrogel, resulted in significantly greater improvements in acne vulgaris (reduced lesion counts and ISGA) than either drug alone or vehicle and effectively treated both non-inflammatory and inflammatory lesions with a convenient, once-daily application.
1 . A method for treating non-inflammatory lesions of acne vulgaris, said method comprising:
administering a composition comprising clindamycin or a pharmaceutically acceptable salt or a prodrug thereof to a subject, to treat said non-inflammatory lesions.
2 . The method of claim 1 , wherein said composition comprises clindamycin phosphate.
3 . The method of claim 2 , wherein said composition contains clindamycin phosphate at 0.25% to about 3% w/w.
4 . The method of claim 3 , wherein said composition contains clindamycin phosphate at 1.0% w/w.
5 . The method of claim 1 , wherein said composition is a hydrogel formulation.
6 . The method of claim 1 , wherein said composition is administered once daily.
7 . A method for treating inflammatory lesions of acne vulgaris, said method comprising:
administering a composition comprising tretinoin to a subject, to treat said inflammatory lesions.
8 . The method of claim 7 , wherein said composition comprises about 0.01% to about 1% tretinoin.
9 . The method of claim 8 , wherein said composition comprises about 0.025% tretinoin.
10 . The method of claim 7 , wherein said composition is a hydrogel formulation.
11 . The method of claim 7 , wherein said composition is administered once daily.
12 . A method for treating acne vulgaris, said method comprising:
administering a composition comprising a combination of active agents comprising clindamycin and tretinoin to a subject, wherein the median time to 50% reduction of total lesion count is shorter than for either active agent alone.
13 . The method of claim 12 , wherein said composition comprises clindamycin phosphate.
14 . The method of claim 13 , wherein said composition contains clindamycin phosphate at 1.0% w/w.
15 . The method of claim 12 , wherein said composition comprises about 0.01% to about 1% tretinoin.
16 . The method of claim 15 , wherein said composition comprises about 0.025% tretinoin.
17 . The method of claim 12 , wherein said composition is a hydrogel formulation.
18 . The method of claim 12 , wherein said composition is administered once daily.
19 . The method of claim 12 , wherein said composition treats both inflammatory and non-inflammatory lesions.
20 . The method of claim 18 , wherein said composition is administered over a period of 8 weeks.
21 . The method of claim 20 , wherein said subject has an Investigator's Static Global Assessment (ISGA) of clear or almost clear.